Screener
Syndax Pharmaceuticals SNDX Cost Of Product Sales
Cost Of Product Sales at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Syndax Pharmaceuticals in its filing.
Tagged under the XBRL concept sndx:CostOfProductSales.
The source filing: Syndax Pharmaceuticals’s 10-Q, filed April 30, 2026.
- Filed
- Apr 30, 2026, 4:04 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-197154
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Collaboration revenue, net | 15,941 | — |
| Total revenues | 64,864 | 20,042 |
| Operating expenses: | ||
| Cost of product sales | $2,633 | $885 |
| Research and development | 58,845 | 61,636 |
| Selling, general and administrative | 37,588 | 41,031 |
| Collaboration loss | — | 247 |
| Total operating expenses | 99,066 | 103,799 |
Item 1: Financial Statements
FAQ
- What is Syndax Pharmaceuticals's cost of product sales?
- Syndax Pharmaceuticals (SNDX) reported cost of product sales of $2.63M in Q1 2026.
- How has Syndax Pharmaceuticals's cost of product sales changed year-over-year?
- Syndax Pharmaceuticals's cost of product sales increased by 197.5% year-over-year, from $885K to $2.63M.
- What does cost of product sales mean?
- This metric represents the direct costs associated with the production and manufacturing of pharmaceutical products sold to customers. It typically includes raw materials, labor, and overhead directly attributable to the goods recognized as revenue during the period. For a clinical-stage company, this reflects the initial commercialization costs and the efficiency of the supply chain for approved therapies.
Ask your AI about Syndax Pharmaceuticals's cost of product sales.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude